GB201321731D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB201321731D0
GB201321731D0 GBGB1321731.0A GB201321731A GB201321731D0 GB 201321731 D0 GB201321731 D0 GB 201321731D0 GB 201321731 A GB201321731 A GB 201321731A GB 201321731 D0 GB201321731 D0 GB 201321731D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1321731.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Priority to GBGB1321731.0A priority Critical patent/GB201321731D0/en
Publication of GB201321731D0 publication Critical patent/GB201321731D0/en
Priority to ES14808644T priority patent/ES2743190T3/es
Priority to CA2930912A priority patent/CA2930912C/en
Priority to EP14808644.0A priority patent/EP3080133B1/en
Priority to PCT/EP2014/076842 priority patent/WO2015086504A1/en
Priority to BR112016011522-8A priority patent/BR112016011522B1/pt
Priority to US15/038,986 priority patent/US10273247B2/en
Priority to JP2016537505A priority patent/JP6483700B2/ja
Priority to CN201480067061.8A priority patent/CN105814065B/zh
Priority to RU2016127226A priority patent/RU2683940C1/ru
Priority to TR2019/10983T priority patent/TR201910983T4/tr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB1321731.0A 2013-12-09 2013-12-09 Therapeutic agents Ceased GB201321731D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1321731.0A GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
TR2019/10983T TR201910983T4 (tr) 2013-12-09 2014-12-08 Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.
PCT/EP2014/076842 WO2015086504A1 (en) 2013-12-09 2014-12-08 Imidazothiazole derivatives as modulators of tnf activity
CA2930912A CA2930912C (en) 2013-12-09 2014-12-08 Fused 5-membered heteroaryl-imidazole derivatives as modulators of tnf activity
EP14808644.0A EP3080133B1 (en) 2013-12-09 2014-12-08 Imidazothiazole derivatives as modulators of tnf activity
ES14808644T ES2743190T3 (es) 2013-12-09 2014-12-08 Derivados de imidazotizol como moduladores de la actividad de TNF
BR112016011522-8A BR112016011522B1 (pt) 2013-12-09 2014-12-08 Derivados de imidazotiazol como moduladores de atividade de tnf
US15/038,986 US10273247B2 (en) 2013-12-09 2014-12-08 Imidazothiazole derivatives as modulators of TNF activity
JP2016537505A JP6483700B2 (ja) 2013-12-09 2014-12-08 Ｔｎｆ活性のモジュレーターとしてのイミダゾチアゾール誘導体
CN201480067061.8A CN105814065B (zh) 2013-12-09 2014-12-08 用作tnf活性调节剂的咪唑并噻唑衍生物
RU2016127226A RU2683940C1 (ru) 2013-12-09 2014-12-08 Производные имидазотиазола в качестве модуляторов активности tnf

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1321731.0A GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB201321731D0 true GB201321731D0 (en) 2014-01-22

Family

ID=50000414

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1321731.0A Ceased GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents

Country Status (11)

Country Link
US (1) US10273247B2 (https=)
EP (1) EP3080133B1 (https=)
JP (1) JP6483700B2 (https=)
CN (1) CN105814065B (https=)
BR (1) BR112016011522B1 (https=)
CA (1) CA2930912C (https=)
ES (1) ES2743190T3 (https=)
GB (1) GB201321731D0 (https=)
RU (1) RU2683940C1 (https=)
TR (1) TR201910983T4 (https=)
WO (1) WO2015086504A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TW201920202A (zh) * 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
WO2022100727A1 (zh) * 2020-11-16 2022-05-19 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463212A1 (en) * 1990-06-27 1992-01-02 Nikken Chemicals Co., Ltd. Imidazo[2,1-b]thiazole compound anti-ulcer agent containing the same
US5577987A (en) 1994-07-07 1996-11-26 Precise Exercise Equipment Co. Abdominal exerciser device
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JP2003525291A (ja) * 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
JP2002167389A (ja) * 2000-09-20 2002-06-11 Nikken Chem Co Ltd 新規チアゾールニ環化合物
CA2523336A1 (en) * 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
CN1823072A (zh) * 2003-05-15 2006-08-23 艾科尔公司 作为p38抑制剂的咪唑并噻唑和咪唑并噁唑衍生物
CA2526285A1 (en) * 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
WO2011132048A1 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物

Also Published As

Publication number Publication date
RU2683940C1 (ru) 2019-04-03
JP6483700B2 (ja) 2019-03-13
US20160376290A1 (en) 2016-12-29
RU2016127226A (ru) 2018-01-23
CN105814065A (zh) 2016-07-27
JP2016539968A (ja) 2016-12-22
WO2015086504A1 (en) 2015-06-18
ES2743190T3 (es) 2020-02-18
CA2930912A1 (en) 2015-06-18
BR112016011522A2 (https=) 2017-08-08
CA2930912C (en) 2021-10-26
CN105814065B (zh) 2018-11-23
US10273247B2 (en) 2019-04-30
BR112016011522B1 (pt) 2022-10-25
EP3080133A1 (en) 2016-10-19
TR201910983T4 (tr) 2019-08-21
EP3080133B1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
IL263026A (en) Combination therapy containing ibrutinib
GB201321743D0 (en) Therapeutic agents
GB201321746D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
AU356625S (en) Rollator
GB201321737D0 (en) Therapeutic Agents
GB201321748D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201321731D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic
GB201321749D0 (en) Therapeutic agents
GB201310755D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)